Merck reported strong first-quarter earnings that exceeded expectations, driven by robust sales of key products like JANUVIA and GARDASIL. The company raised its full-year EPS guidance, signaling confidence in continued growth. Despite setbacks with ARCOXIA and gaboxadol, the overall positive performance and optimistic outlook are likely to have a positive impact on the stock price in the short term.

[1]